These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 34436547)

  • 21. Ushering in the next generation of precision trials for pediatric cancer.
    DuBois SG; Corson LB; Stegmaier K; Janeway KA
    Science; 2019 Mar; 363(6432):1175-1181. PubMed ID: 30872517
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Who writes dermatology randomized controlled trials? The need to specify the role of medical writers.
    Steele L; Lee HL; Earp E; Hong A; Thomson J
    Clin Exp Dermatol; 2021 Aug; 46(6):1086-1088. PubMed ID: 33914938
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The changing face of clinical trials in the personalized medicine and immuno-oncology era: report from the international congress on clinical trials in Oncology & Hemato-Oncology (ICTO 2017).
    Golan T; Milella M; Ackerstein A; Berger R
    J Exp Clin Cancer Res; 2017 Dec; 36(1):192. PubMed ID: 29282151
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Precision medicine in pediatric oncology.
    Forrest SJ; Geoerger B; Janeway KA
    Curr Opin Pediatr; 2018 Feb; 30(1):17-24. PubMed ID: 29189430
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Precision oncology: a strategy we were not ready to deploy.
    Fojo T
    Semin Oncol; 2016 Feb; 43(1):9-12. PubMed ID: 26970119
    [No Abstract]   [Full Text] [Related]  

  • 26. Next-Generation Sequencing in Oncology in the Era of Precision Medicine.
    Blumenthal GM; Mansfield E; Pazdur R
    JAMA Oncol; 2016 Jan; 2(1):13-4. PubMed ID: 26540172
    [No Abstract]   [Full Text] [Related]  

  • 27. Stopping a trial early in oncology: for patients or for industry?
    Whitehead J; Cobo E
    Ann Oncol; 2008 Aug; 19(8):1512-1513. PubMed ID: 18621741
    [No Abstract]   [Full Text] [Related]  

  • 28. Randomized controlled trials in the era of molecular oncology: methodology, biomarkers, and end points.
    Kay A; Higgins J; Day AG; Meyer RM; Booth CM
    Ann Oncol; 2012 Jun; 23(6):1646-51. PubMed ID: 22048151
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Orientation of medical oncology treatment in precision medicine era].
    Shi Y; Sun Y
    Zhonghua Yi Xue Za Zhi; 2015 Aug; 95(31):2518-21. PubMed ID: 26711383
    [No Abstract]   [Full Text] [Related]  

  • 30. Professional medical writing support and the quality of randomised controlled trial reporting: a cross-sectional study.
    Gattrell WT; Hopewell S; Young K; Farrow P; White R; Wager E; Winchester CC
    BMJ Open; 2016 Feb; 6(2):e010329. PubMed ID: 26899254
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patient-centric trials for therapeutic development in precision oncology.
    Biankin AV; Piantadosi S; Hollingsworth SJ
    Nature; 2015 Oct; 526(7573):361-70. PubMed ID: 26469047
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stopping a trial early in oncology: for patients or for industry?
    Bradbury P; Meyer R; Pater J; Tu D; Seymour L; Shepherd L; Eisenhauer E
    Ann Oncol; 2009 Feb; 20(2):395-6. PubMed ID: 19150952
    [No Abstract]   [Full Text] [Related]  

  • 33. Early Returns From the Era of Precision Medicine.
    Cutler DM
    JAMA; 2020 Jan; 323(2):109-110. PubMed ID: 31935015
    [No Abstract]   [Full Text] [Related]  

  • 34. Precision in psychiatry.
    van der Stel JC
    Acta Psychiatr Scand; 2015 Oct; 132(4):310-1. PubMed ID: 26137894
    [No Abstract]   [Full Text] [Related]  

  • 35. Evolution of the Randomized Clinical Trial in the Era of Precision Oncology.
    Del Paggio JC; Berry JS; Hopman WM; Eisenhauer EA; Prasad V; Gyawali B; Booth CM
    JAMA Oncol; 2021 May; 7(5):728-734. PubMed ID: 33764385
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multidisciplinary and interprofessional collaboration as a necessity to drive modern oncology research trials in the era of precision oncology.
    Tan J; Boon IS
    J Med Imaging Radiat Sci; 2022 Mar; 53(1):179-180. PubMed ID: 34922880
    [No Abstract]   [Full Text] [Related]  

  • 37. Phase I trials and therapeutic intent in the age of precision oncology: What is a patient's chance of response?
    Tao DL; Kartika T; Tran A; Prasad V
    Eur J Cancer; 2020 Nov; 139():20-26. PubMed ID: 32957010
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Precision medicine in oncology: Challenges, stakes and new paradigms].
    Cox S; Rousseau-Tsangaris M; Abou-Zeid N; Dalle S; Leurent P; Cutivet A; Le HH; Kotb S; Bogaert B; Gardette R; Baran Y; Holder JM; Lerner L; Blay JY; Cambrosio A; Tredan O; Denèfle P
    Bull Cancer; 2019 Feb; 106(2):97-104. PubMed ID: 30713005
    [No Abstract]   [Full Text] [Related]  

  • 39. Role of Key Guidelines in an Era of Precision Oncology: A Primer for the Radiologist.
    Gan JM; Kikano EG; Smith DA; Bui MT; Tirumani SH; Ramaiya NH
    AJR Am J Roentgenol; 2021 Apr; 216(4):1112-1125. PubMed ID: 33502227
    [No Abstract]   [Full Text] [Related]  

  • 40. New challenges for comparative effectiveness in oncology: choice of primary end points for randomized clinical trials.
    Freidlin B; Abrams JS; Korn EL
    J Comp Eff Res; 2013 Sep; 2(5):469-81. PubMed ID: 24236744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.